parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in oligodendrocytes (739 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.50
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 107	0.82
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12001

CNDP1 in oligodendrocytes, braak+0.42 (p 0.258) → -0.03 (p 0.946)receipt 12008
CNDP1 in dopamine neurons, braak+0.37 (p 0.334) → +0.14 (p 0.724)receipt 12009

receipt 12009: CNDP1 in dopamine neurons, braak

power: full sample +0.34 (p 0.167, n 18), 95% CI -0.15 to +0.70. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.35 (p 0.153, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.116, n 18). could be the mix.
skeptic: leave-one-out range +0.26 to +0.47, sign flips 0; without severely affected donors +0.34 (p 0.167, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CNDP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12008: CNDP1 in oligodendrocytes, braak

power: full sample +0.26 (p 0.306, n 18), 95% CI -0.24 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.26 (p 0.306, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.24 (p 0.341, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.41, sign flips 0; without severely affected donors +0.26 (p 0.306, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CNDP1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts